Illumina, has announced the launch of BioInsight, a new business unit aimed at addressing the growing demand from researchers and pharmaceutical companies for deeper biological insights derived from large-scale multiomic data. By leveraging Illumina’s expertise in sequencing, data analysis, software, and AI, BioInsight will empower partners and customers to identify drug targets, explore biological pathways, uncover novel disease mechanisms, and drive the next generation of biological discoveries. This initiative underscores Illumina’s commitment to advancing science and healthcare while supporting the company’s long-term growth.
BioInsight will focus on creating data assets, software, and AI solutions to accelerate breakthroughs in the life sciences. The unit will be led by Rami Mehio, who joins Illumina’s executive leadership team as senior vice president and general manager. Mehio previously led Illumina's Global Software & Informatics team for four years.
“Working together with our customers, we are going beyond sequencing and breaking the barrier between omics data generation and transformative insights,” said Jacob Thaysen, CEO of Illumina. “BioInsight, under Rami's guidance, will strengthen Illumina's leadership at the intersection of sequencing, software, and AI, with a focus on supporting pharma in drug target discovery and development.”
Key focus areas for BioInsight include collaborating with national initiatives and industry partners to drive large-scale genetic and biological data generation, developing software solutions to analyze complex, multimodal data at population scale, providing platforms for private and secure access to research and pharmaceutical partners, and building AI tools through strategic partnerships to create a comprehensive ecosystem for large-scale multimodal data analysis.
“We are at a pivotal moment in science and technology,” said Rami Mehio. “The dramatic reduction in sequencing costs has unlocked the ability to generate multiomic data at an unprecedented scale. At the same time, we are witnessing an extraordinary rise in AI capabilities. The confluence of these two forces is transforming how we derive biological insights, and Illumina is committed to partnering with our customers and collaborators to develop the largest, highest-quality datasets and the AI-driven tools that turn this data into meaningful discoveries.”
Life sciences research is accelerating rapidly as scientists gain the ability to collect and interpret unprecedented volumes of multiomic data. Advanced AI and software tools are crucial for deriving actionable insights from these complex datasets, which can accelerate drug target discovery, improve disease diagnosis, and enhance therapeutic development. BioInsight has been structured to support the essential functions required to achieve these goals.
BioInsight will facilitate data generation through large national research initiatives, collaboration with corporate partners to develop valuable data assets, and support for large-scale federated data networks. The focus will expand beyond traditional genomics to include multiomic and advanced biological data types such as perturb-seq.
BioInsight aims to harness all available multimodal data to create tools and resources that help partners achieve meaningful results more efficiently. These tools will enable scientists to quickly identify patterns, discover new drug targets, and improve disease diagnosis and treatment. Alongside developing in-house tools and models, Illumina plans to collaborate with industry leaders to foster a broad ecosystem of AI-driven solutions leveraging its data assets.
With this initiative, BioInsight and Illumina are positioned to accelerate access to rich omics data insights, helping researchers and pharma companies achieve faster, more efficient, and transformative discoveries.
Also Read More